To take this forward, we selected Gsk3β, ranked 38th, and Tomm20, ranked 44th (Supplementary Table S5), because of the existing literature arguing that they act within pathways that are potentially involved in the pathobiology of PD, and because inhibitors of these pathways are being pursued as potential therapeutics [21,42–47]. Here, GSK3B is linked to Parkinson disease.